Linxin Liu Selected Research

Linxin Liu Research Topics

7	Neoplasms (Cancer) 04/2024 - 01/2015
4	Carcinogenesis 04/2024 - 01/2015
3	Neoplasm Metastasis (Metastasis) 02/2022 - 11/2015
2	Cognitive Dysfunction 03/2024 - 01/2021
1	Squamous Cell Carcinoma of Head and Neck 04/2024
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2022
1	Lung Neoplasms (Lung Cancer) 02/2022
1	Liver Neoplasms (Liver Cancer) 01/2022
1	Chronic Renal Insufficiency 01/2022
1	Alzheimer Disease (Alzheimer's Disease) 01/2021
1	Stomach Neoplasms (Stomach Cancer) 10/2019
1	Melanoma (Melanoma, Malignant) 10/2017
1	Inflammation (Inflammations) 11/2015
1	Tics (Tic) 11/2015
1	Lung Injury 01/2015
1	Wounds and Injuries (Trauma) 01/2015
1	Pneumonia (Pneumonitis) 01/2015
1	Leukemia 07/2009

3	Biomarkers (Surrogate Marker)IBA 02/2022 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 04/2024 - 11/2015
1	LigandsIBA 04/2024
1	Immune Checkpoint ProteinsIBA 04/2024
1	NucleotidesIBA 12/2023
1	RNA (Ribonucleic Acid)IBA 02/2022
1	MicroRNAs (MicroRNA)IBA 02/2022
1	cholanic acidIBA 01/2022
1	obeticholic acidIBA 01/2022
1	AcidsIBA 01/2022
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2022
1	ApolipoproteinsIBA 01/2021
1	LipidsIBA 01/2021
1	Glucose (Dextrose)FDA LinkGeneric 01/2021
1	Apolipoproteins E (ApoE)IBA 01/2021
1	Antimalarials (Antimalarial Agents)IBA 10/2019
1	artemisinin (artemisinine)IBA 10/2019
1	ArtesunateIBA 10/2019
1	UreaseIBA 10/2019
1	artenimol (dihydroartemisinin)IBA 10/2019
1	SaponinsIBA 10/2017
1	ConnexinsIBA 10/2017
1	dioscinIBA 10/2017
1	Connexin 43 (Connexin43)IBA 10/2017
1	Adenosine Triphosphatases (ATPase)IBA 11/2015
1	vadimezanIBA 11/2015
1	Cadherins (E-Cadherin)IBA 11/2015
1	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 11/2015
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 11/2015
1	notoginsenoside R1IBA 01/2015
1	Urethane (Ethyl Carbamate)IBA 01/2015
1	shikoninIBA 01/2015
1	AconitineIBA 01/2015
1	Histones (Histone)IBA 07/2009
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 07/2009

2	Therapeutics 02/2022 - 11/2015
1	Immunotherapy 04/2024
1	Activities of Daily Living (ADL) 03/2024